Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Enzymatic Bioconjugation: A Perspective from the Pharmaceutical Industry. | JACS Au | 2023 | 37234110 | PubTator, text mining | PubMed |
| TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). | Cancer Treat Rev | 2023 | 37230055 | PubTator, text mining | PubMed |
| Targeting Replication Stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: A Phase I Clinical Trial. | Clin Cancer Res | 2023 | 37227187 | PubTator, text mining | PubMed |
| A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7. | Cancer Lett | 2023 | 37217069 | PubTator, text mining | PubMed |
| Trop2 Promotes Vimentin Expression and Induces Epithelial Stromal Transformation, Invasion and Metastasis of Gastric Cancer Cells by Regulating β-Catenin. | Cell Mol Biol (Noisy-le-grand) | 2023 | 37213150 | PubTator, text mining | PubMed |
| Development, efficacy and side effects of antibody‑drug conjugates for cancer therapy (Review). | Mol Clin Oncol | 2023 | 37206431 | PubTator, text mining | PubMed |
| Apposition of Fibroblasts With Metaplastic Gastric Cells Promotes Dysplastic Transition. | Gastroenterology | 2023 | 37196797 | PubTator, text mining | PubMed |
| Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications. | EJNMMI Res | 2023 | 37195374 | PubTator, text mining | PubMed |
| Cytosolic EpCAM cooperates with H-Ras to regulate epithelial to mesenchymal transition through ZEB1. | PLoS One | 2023 | 37192201 | PubTator, text mining | PubMed |
| Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. | Cancers (Basel) | 2023 | 37190133 | PubTator, text mining | PubMed |
| 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review. | Curr Oncol | 2023 | 37185443 | PubTator, text mining | PubMed |
| Scoring System and Diagnosis of Papillary Thyroid Carcinoma Using Human Bone Marrow Endothelium Marker-1, Cytokeratin 19, and Galectin-3. | Med J Islam Repub Iran | 2023 | 37180862 | PubTator, text mining | PubMed |
| SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups. | World J Gastroenterol | 2023 | 37179584 | PubTator, text mining | PubMed |
| Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. | ESMO Open | 2023 | 37178669 | PubTator, text mining | PubMed |
| Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies. | Int J Mol Sci | 2023 | 37175833 | PubTator, text mining | PubMed |
| Prediction of Early- and Late-Onset Pre-Eclampsia in the Preclinical Stage via Placenta-Specific Extracellular miRNA Profiling. | Int J Mol Sci | 2023 | 37175711 | PubTator, text mining | PubMed |
| Extraction, Purification, Structural Characteristics, Biological Activities, and Applications of the Polysaccharides from Zingiber officinale Roscoe. (Ginger): A Review. | Molecules | 2023 | 37175266 | PubTator, text mining | PubMed |
| Corneal Regeneration Using Gene Therapy Approaches. | Cells | 2023 | 37174680 | PubTator, text mining | PubMed |
| Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology. | Cancers (Basel) | 2023 | 37174125 | PubTator, text mining | PubMed |
| The Challenges of Treating Patients with Breast Cancer and Obesity. | Cancers (Basel) | 2023 | 37173991 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=57